Vascular Biogenics (Nasdaq:VBLT) - Hisse Senedi Fiyatı, Haberler ve Analizler

VBLT Stoklara Genel Bakış

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Daha fazla detay

VBLT temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Risk Analizi

Kazançlar son 5 yılda yılda 14.9% oranında azaldı

Geliri 1 milyon ABD dolarından az ( $481K )

Hissedarlar geçen yıl sulandırıldı

Anlamlı bir piyasa değeri yok ( $12M )

+ 1 daha fazla risk

Vascular Biogenics Ltd. Rakipler

Ensysce Biosciences

NasdaqCM:ENSC

US$8.4m

Vaccinex

NasdaqCM:VCNX

US$9.7m

Eagle Pharmaceuticals

OTCPK:EGRX

US$12.4m

America Great Health

OTCPK:AAGH

US$10.6m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Vascular Biogenics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.16
52 Haftanın En Yüksek Seviyesi	US$0.32
52 Haftanın En Düşük Seviyesi	US$0.10
Beta	0.71
11 Aylık Değişim	-33.33%
3 Aylık Değişim	-45.07%
1 Yıllık Değişim	9.17%
33 Yıllık Değişim	-86.55%
5 Yıllık Değişim	-88.53%
Halka arzdan bu yana değişim	-97.33%

Son Haberler & Güncellemeler

Recent updates

VBL Therapeutics receives non-compliance letter from Nasdaq

Sep 01

VBL Therapeutics GAAP EPS of -$0.12

Aug 15

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Jul 19

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

May 18

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Sep 03

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

Mar 17

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

Jan 28

VBL Therapeutics expands the ovarian cancer trial in Europe

Dec 29

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

Dec 24

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 19

VBL Therapeutics EPS beats by $0.01, misses on revenue

Nov 16

Hissedar Getirileri

	VBLT	US Biotechs	US Pazar
7D	-34.5%	4.0%	2.2%
1Y	9.2%	18.3%	32.6%

Getiri vs. Endüstri: VBLT geçen yıl % 18.3 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: VBLT geçen yıl % 32.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is VBLT's price volatile compared to industry and market?
VBLT volatility
VBLT Average Weekly Movement	13.5%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: VBLT hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: VBLT 'nin haftalık oynaklığı ( 14% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2000	7	Dror Harats	www.vblrx.com

Vascular Biogenics Ltd. Temel Bilgiler Özeti

Vascular Biogenics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
VBLT temel i̇stati̇sti̇kler
Piyasa değeri	US$12.11m
Kazançlar(TTM)	-US$15.95m
Gelir(TTM)	US$481.00k

25.2x

P/S Oranı

-0.8x

F/K Oranı

VBLT aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
VBLT gelir tablosu (TTM)
Gelir	US$481.00k
Gelir Maliyeti	US$17.00k
Brüt Kâr	US$464.00k
Diğer Giderler	US$16.42m
Kazançlar	-US$15.95m

Son Raporlanan Kazançlar

Jun 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.21
Brüt Marj	96.47%
Net Kâr Marjı	-3,317.05%
Borç/Özkaynak Oranı	0%

VBLT uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

VBLT Stoklara Genel Bakış

Risk Analizi

Vascular Biogenics Ltd. Rakipler

NasdaqCM:ENSC

US$8.4m

NasdaqCM:VCNX

US$9.7m

OTCPK:EGRX

US$12.4m

OTCPK:AAGH

US$10.6m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Vascular Biogenics Ltd.(NasdaqCM:VBLT) dropped from NASDAQ Composite Index

Notable Labs, Inc. completed the acquisition of Vascular Biogenics Ltd. (NasdaqGM:VBLT) from Aurum Ventures MKI Ltd. and others in reverse merger transaction.

Vascular Biogenics Ltd. Approves Board Appointments

Vascular Biogenics Ltd. Receives Non-Compliance Notice from Nasdaq

Full year 2022 earnings released: US$0.42 loss per share (vs US$0.45 loss in FY 2021)

An unknown buyer entered into an agreement to acquire Manufacturing facility in Modiin, Israel and certain related assets from Vascular Biogenics Ltd. (NasdaqGM:VBLT) for $7.1 million.

Recent updates

Vascular Biogenics Ltd.(NasdaqCM:VBLT) dropped from NASDAQ Composite Index

Notable Labs, Inc. completed the acquisition of Vascular Biogenics Ltd. (NasdaqGM:VBLT) from Aurum Ventures MKI Ltd. and others in reverse merger transaction.

Vascular Biogenics Ltd. Approves Board Appointments

Vascular Biogenics Ltd. Receives Non-Compliance Notice from Nasdaq

Full year 2022 earnings released: US$0.42 loss per share (vs US$0.45 loss in FY 2021)

An unknown buyer entered into an agreement to acquire Manufacturing facility in Modiin, Israel and certain related assets from Vascular Biogenics Ltd. (NasdaqGM:VBLT) for $7.1 million.

VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

VBL Therapeutics receives non-compliance letter from Nasdaq

VBL Therapeutics GAAP EPS of -$0.12

VBL Therapeutics Announces Workforce Reduction

Price target increased to US$6.00

Vbl Therapeutics Announces Top-Line Data from Phase 3 Oval Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer

VBL Therapeutics' late-stage trial for ovarian cancer treatment does not meet main goals

Vascular Biogenics Ltd., Annual General Meeting, Jul 07, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Here's Why We're Watching Vascular Biogenics' (NASDAQ:VBLT) Cash Burn Situation

Vascular Biogenics Ltd. to Report Q1, 2022 Results on May 17, 2022

Consensus forecasts updated

No longer forecast to breakeven

VBL Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation for Ofra-Vec (Ofranergene Obadenovec or VB-111) in Combination with Paclitaxel for Treatment of Platinum-Resistant Ovarian Cancer

Consensus forecasts updated

VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned

Forecast to breakeven in 2024

Vascular Biogenics Ltd. announced that it expects to receive €15 million in funding from European Innovation Council

Third quarter 2021 earnings released: US$0.092 loss per share (vs US$0.12 loss in 3Q 2020)

VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the Oval Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer

Vascular Biogenics Trial Nears Full Enrollment, Price Could Jump

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 2Q 2020)

High number of new directors

VBL Therapeutics Provides Update on Oval, A Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

VBL Therapeutics Announces Addition of Progression Free Survival as A Second Primary Endpoint in OVAL, A Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

Vbl Therapeutics to Provide an Update on the Oval Phase 3 Registration Enabling Study of Vb-111 in Ovarian Cancer At the 2021

Price target increased to US$5.20

Consensus forecasts updated

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1Q 2020)

Consensus forecasts updated

Full year 2020 earnings released: US$0.56 loss per share (vs US$0.54 loss in FY 2019)

Vascular Biogenics Ltd. to Report Q4, 2020 Results on Mar 25, 2021

How Much Are Vascular Biogenics Ltd. (NASDAQ:VBLT) Insiders Spending On Buying Shares?

VBL Therapeutics Announces Patient Dosing Initiated in Randomized, Controlled and Blinded Trial of VB-111 in Patients with Recurrent Glioblastoma Multiforme

VBL Therapeutics Announces Data Safety Monitoring Committee Provides Green Light to Advance the OVAL Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients

How Much Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Do Insiders Own?

New 90-day high: US$2.50

Price target raised to US$4.50

VBL Therapeutics Announces First Patient in Europe in the OVAL Trial

VBL Therapeutics expands the ovarian cancer trial in Europe

Is Vascular Biogenics (NASDAQ:VBLT) In A Good Position To Deliver On Growth Plans?

New 90-day high: US$1.96

Vascular Biogenics Ltd. (NASDAQ:VBLT) Just Reported And Analysts Have Been Cutting Their Estimates

Third quarter 2020 earnings released: US$0.12 loss per share

Revenue and earnings miss expectations

VBL Therapeutics EPS beats by $0.01, misses on revenue

New 90-day low: US$1.07

Vascular Biogenics Ltd. to Report Q3, 2020 Results on Nov 16, 2020

Vascular Biogenics Ltd. Announces Resignation of Susan Kelley as an Independent Director

Vascular Biogenics Ltd. Announces Board Changes

New 90-day low - US$1.16

First half earnings released